Omar Mukhtar

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

Mikhail Kosiborod, Russell Esterline, Remo H.M. Furtado et al. · The Lancet Diabetes & Endocrinology · 2021 · 245 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Effects of <b>da</b> pagliflozin on prevention of major clinical events and recovery in patients with <b>re</b> spiratory failure because of COVID‐ <b>19</b> : Design and rationale for the DARE‐19 study

Mikhail Kosiborod, Otávio Berwanger, Gary G. Koch et al. · Diabetes Obesity and Metabolism · 2020 · 48 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The Miraculous Fever Tree: Malaria, Medicine and the Cure that Changed the World

Omar Mukhtar · BMJ · 2003 · 23 citations · Full text

Veterinary Medicine, Infectious Diseases, Clinical Medicine +9

Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection

Hiddo J.L. Heerspink, Remo H.M. Furtado, Otávio Berwanger et al. · Clinical Journal of the American Society of Nephrology · 2022 · 20 citations · Full text

Pharmacy, Nephrology, Pharmacotherapy +13

A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program—AIM-HY INFORM trial

Omar Mukhtar, Joseph Cheriyan, John R. Cockcroft et al. · American Heart Journal · 2018 · 17 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17